GCP
ALDX icon

GSA Capital Partners’s Aldeyra Therapeutics ALDX Stock Holding History

GSA Capital Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
472,564
+225,370
+91% +$387K 0.06% 500
2026
Q1 		$418K Buy
247,194
+150,277
+155% +$658K 0.03% 1026
2025
Q4 		$502K Sell
96,917
-25,747
-21% -$132K 0.04% 805
2025
Q3 		$640K Buy
122,664
+49,368
+67% +$257K 0.05% 680
2025
Q2 		$281K Buy
+73,296
New +$189K 0.02% 1297
2024
Q3 		– Sell
-16,020
Closed -$53K – 1562
2024
Q2 		$53K Sell
16,020
-9,229
-37% -$36.1K ﹤0.01% 1563
2024
Q1 		$83K Sell
25,249
-143,514
-85% -$472K 0.01% 1504
2023
Q4 		$592K Buy
168,763
+153,499
+1,006% +$474K 0.05% 684
2023
Q3 		$102K Sell
15,264
-64,443
-81% -$478K 0.01% 1384
2023
Q2 		$669K Sell
79,707
-13,237
-14% -$130K 0.07% 553
2023
Q1 		$923K Sell
92,944
-50,264
-35% -$355K 0.09% 357
2022
Q4 		$997K Buy
143,208
+39,360
+38% +$225K 0.12% 208
2022
Q3 		$555K Buy
+103,848
New +$623K 0.07% 490
2022
Q2 		– Sell
-59,934
Closed -$266K – 1361
2022
Q1 		$266K Sell
59,934
-66,180
-52% -$264K 0.04% 980
2021
Q4 		$504K Buy
126,114
+22,838
+22% +$174K 0.06% 592
2021
Q3 		$907K Buy
103,276
+80,407
+352% +$738K 0.09% 356
2021
Q2 		$259K Buy
+22,869
New +$275K 0.03% 1035
2021
Q1 		– Sell
-61,220
Closed -$420K – 1068
2020
Q4 		$420K Buy
61,220
+35,717
+140% +$251K 0.07% 535
2020
Q3 		$189K Buy
+25,503
New +$165K 0.03% 1021

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

GSA Capital Partners's ALDX Position: Q2 2026 in Review

GSA Capital Partners increased its Aldeyra Therapeutics (ALDX) stake by 91% in Q2 2026, buying an estimated $387K and bringing the position to 472,564 shares worth $1.01M. The position accounts for 0.06% of the portfolio, ranked #500.

GSA Capital Partners first reported a position in ALDX in Q3 2020 and has held it in 19 quarters since. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • GSA Capital Partners held 472,564 shares of Aldeyra Therapeutics worth $1.01M as of Q2 2026.
  • GSA Capital Partners bought 225,370 Aldeyra Therapeutics shares in Q2 2026, an estimated $387K.
  • Aldeyra Therapeutics made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #500 holding.
  • GSA Capital Partners first reported a position in Aldeyra Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.